Blueprint Medicines to Present Preclinical Data on RET Inhibitors in an Oral Presentation at American Association for Cancer Research Annual Meeting
Activating RET kinase fusions and mutations have emerged as important drivers of disease in a variety of cancers, including non-small cell lung cancer (NSCLC) and papillary and medullary thyroid cancers. RET kinase fusions are found in 1-2% of lung adenocarcinomas, and RET activating mutations have been identified in approximately 50% of medullary thyroid cancers and approximately 10% of papillary thyroid cancers. In addition,
In preclinical studies to be presented at AACR,
Oral Presentation Details:
- Date & Time:
Monday, Apr 18, 2016 ,3:05 PM - 3:20 PM - Presentation Title: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors
- Abstract Number: 2641
- Location: New Orleans Theater A,
Morial Convention Center
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the potential inability of approved multi-kinase inhibitors to sufficiently inhibit RET and
Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-preclinical-data-on-ret-inhibitors-in-an-oral-presentation-at-american-association-for-cancer-research-annual-meeting-300237336.html
SOURCE
Investor Relations: Kristin Williams, Blueprint Medicines Corporation, 617-714-6674, KWilliams@blueprintmedicines.com; Media Relations: Dan Quinn, Ten Bridge Communications, Inc., 781-475-7974, dan@tenbridgecommunications.com